181 related articles for article (PubMed ID: 18221994)
1. Irreversible sensorineural hearing loss due to Imatinib.
Attili VS; Bapsy PP; Anupama G; Lokanatha D
Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
[TBL] [Abstract][Full Text] [Related]
2. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
3. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
4. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
[TBL] [Abstract][Full Text] [Related]
5. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
6. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
7. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
8. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Busuttil DP
Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
[TBL] [Abstract][Full Text] [Related]
9. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Ahmed MS; Kroft SH; Davis NB; King DM; Cheng YC
Leuk Res; 2008 Sep; 32(9):1476-9. PubMed ID: 18308388
[TBL] [Abstract][Full Text] [Related]
10. [Imatinib-induced DRESS].
Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
[TBL] [Abstract][Full Text] [Related]
11. Dermatological toxicity of imatinib mesylate.
Prasad N; Deshmukh C; Biswas G; Bakshi A; Sastry PS; Parikh PM
J Assoc Physicians India; 2005 Apr; 53():298. PubMed ID: 15987015
[No Abstract] [Full Text] [Related]
12. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
Srinivas U; Pillai LS; Kumar R; Pati HP; Saxena R
Am J Hematol; 2007 Apr; 82(4):314-6. PubMed ID: 17013815
[TBL] [Abstract][Full Text] [Related]
13. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Chang H; Shih LY
Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
[TBL] [Abstract][Full Text] [Related]
14. Sensorineural hearing loss following imatinib (Gleevec) administration.
Lin HW; Roberts DS; Kay J; Stankovic KM
Otolaryngol Head Neck Surg; 2012 Feb; 146(2):335-7. PubMed ID: 21753034
[No Abstract] [Full Text] [Related]
15. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
16. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review.
Wahiduzzaman M; Pubalan M
Dermatol Online J; 2008 Dec; 14(12):14. PubMed ID: 19265627
[TBL] [Abstract][Full Text] [Related]
17. Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy.
Yu YH; Shere Y; Vigneswaran N
Tex Dent J; 2012 Aug; 129(8):764-5, 786-8. PubMed ID: 22988661
[No Abstract] [Full Text] [Related]
18. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
19. Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?
Kanda Y; Okamoto S; Tauchi T; Kizaki M; Inokuchi K; Yabe M; Yokoyama K; Ito Y; Kimura Y; Higashihara M; Bessho M; Ando K; Chiba S; Kurokawa M; Oshimi K; Dan K; Ohyashiki K; Ikeda Y;
Am J Hematol; 2008 Nov; 83(11):835-9. PubMed ID: 18785644
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.
Mahapatra M; Mishra P; Kumar R
Ann Hematol; 2007 Jul; 86(7):537-8. PubMed ID: 17287945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
